SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study

Por Kokai-Kun, John, Roberts, Tracey, Coughlin, Olivia, Whalen, Heidi, Le, Charles, Da Costa, Christopher, Sliman, Joseph
Publicado no Open Forum Infect Dis (2017)

The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder

Por Liebowitz, Michael, Croft, Harry A., Kajdasz, Daniel K., Whalen, Heidi, Gallipoli, Susan, Athanasiou, Maria, Reed, Carol R.
Publicado no Psychopharmacol Bull (2011)

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Por Kokai-Kun, John F., Roberts, Tracey, Coughlin, Olivia, Sicard, Eric, Rufiange, Marianne, Fedorak, Richard, Carter, Christian, Adams, Marijke H., Longstreth, James, Whalen, Heidi, Sliman, Joseph
Publicado no Antimicrob Agents Chemother (2017)